Gynecologic Oncology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.
Gynecol Oncol. 2011 Oct;123(1):95-8. doi: 10.1016/j.ygyno.2011.06.024. Epub 2011 Jul 20.
Radical vaginal trachelectomy (RVT) is a revolutionary option for fertility preservation in young women with early cervical tumors. Several series have demonstrated outcomes comparable to radical hysterectomy (RH), but none has addressed the influence of histology. We evaluated the safety of RVT in adenocarcinomas.
Data on surgically treated adenocarcinoma (AC) and squamous cell carcinoma (SCC) cases was taken from a centralized Toronto Cervical Cancer Database. Prognostically important tumor features, lymph node status, and the use of adjuvant therapies were compared. Adenocarcinoma cases treated with RVT were compared to AC cases treated with RH, and to SCC cases that had RVT. Recurrence-free survival was calculated from the date of surgery. Medians, proportions, and survival curves were compared with the Mann Whitney test, the Chi-square test, and the Log Rank test, respectively.
74 patients with AC and 66 patients with SCC undergoing RVT, and 187 cases of AC undergoing RH were analyzed. Patients undergoing RVT were younger than patients having RH (31 vs. 40, p<0.001). Tumor characteristics were similar, but depth of invasion and the frequency of high grade lesions were higher in the RH group (5 mm vs. 3 mm, p<0.001; and 36% vs. 22%, p=0.04). Adjuvant treatment was given more frequently after RH (12% vs. 3%, p<0.05). There was no significant difference in recurrence-free survival between RH and RVT for AC, or between AC and SCC patients treated by RVT.
RVT is a safe alternative for early stage cervical adenocarcinoma in appropriately selected patients wishing to preserve fertility.
根治性阴道子宫颈切除术(RVT)是年轻早期宫颈癌患者保留生育能力的一项革命性选择。有几个系列研究表明其结果与根治性子宫切除术(RH)相当,但都没有涉及组织学的影响。我们评估了 RVT 在腺癌中的安全性。
从多伦多宫颈癌数据库集中获取了接受手术治疗的腺癌(AC)和鳞状细胞癌(SCC)病例的数据。比较了具有预后意义的肿瘤特征、淋巴结状态以及辅助治疗的使用情况。将接受 RVT 治疗的腺癌病例与接受 RH 治疗的 AC 病例以及接受 RVT 治疗的 SCC 病例进行比较。无复发生存率从手术日期开始计算。中位数、比例和生存曲线分别用 Mann-Whitney 检验、卡方检验和对数秩检验进行比较。
分析了 74 例接受 RVT 的 AC 患者和 66 例接受 RVT 的 SCC 患者,以及 187 例接受 RH 的 AC 患者。接受 RVT 的患者比接受 RH 的患者年轻(31 岁 vs. 40 岁,p<0.001)。肿瘤特征相似,但 RH 组的浸润深度和高级别病变的频率更高(5 毫米 vs. 3 毫米,p<0.001;36% vs. 22%,p=0.04)。RH 后辅助治疗的频率更高(12% vs. 3%,p<0.05)。在 RH 和 RVT 治疗的 AC 患者之间,或在接受 RVT 治疗的 AC 和 SCC 患者之间,无复发生存率无显著差异。
在适当选择希望保留生育能力的患者中,RVT 是早期宫颈癌腺癌的一种安全替代方法。